Data Sheet (Cat.No.T15617)

TargetMol

JNJ-38877618

Chemical Properties



CAS No. : 943540-74-7

Formula: C20H12F2N6

Molecular Weight: 374.35

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).
Targets(IC50)	c-Met/HGFR
In vitro	JNJ-38877618 shows nM potency against Met Ampl/mutant and therapy-resistant models. JNJ-38877618 has nM binding affinity (Kd=1.4 nM) and enzyme inhibitory activity against wt and M1268T mutant Met (2 and 3 nM IC50). Met inhibitory effects are assessed in proliferation, colony formation, and motility assays.
In vivo	JNJ-38877618 effectively induces regression in substantial Met-amplified EBC-1 SqNSCLC by dose- and time-dependently inhibiting Met kinase activation, with the inhibition lasting significantly longer than its plasma presence. It entirely halts tumor growth in three distinct models: SNU5 Met amp gastric, U87-MG HGF autocrine glioblastoma, and Hs746T Met exon 14 skipping mutant gastric cancer. Additionally, combination therapies are well tolerated and enhance EGFR-targeted treatments[1].

Solubility Information

Solubility	DMSO: 4.5 mg/mL (12.02 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6713 mL	13.3565 mL	26.713 mL
5 mM	0.5343 mL	2.6713 mL	5.3426 mL
10 mM	0.2671 mL	1.3356 mL	2.6713 mL
50 mM	0.0534 mL	0.2671 mL	0.5343 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78 (13 Suppl):Abstract nr 4791.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481